Adragos Pharma in the news

Prange Group sold its remaining shares in Adragos Pharma, making FSN Capital and management the sole owners, allowing both companies to focus on their respective CDMO growth strategies.

Prange Group sold its remaining shares in Adragos Pharma, leaving FSN Capital VI and management as the sole shareholders, while Adragos Pharma aims for further international expansion and Prange Group focuses on its own CDMO platforms.

Adragos Pharma and Towa Pharmaceutical partnered to manufacture 1.5 billion off-patent tablets annually, boosting Japan's drug supply stability.

Adragos Pharma will manufacture and supply up to 1.5 billion off-patent tablets annually for Towa Pharmaceutical, expanding its Kawagoe plant's capacity.

Adragos Pharma signed a strategic supply pact with Towa Pharmaceutical to manufacture 1.5 billion tablets annually at its expanded Kawagoe facility.

Contract manufacturing organizations are rapidly acquiring pharmaceutical production facilities to expand sterile fill-finish and biologics capacity across the U.S. and Europe.

Kostas Rengis has been named the new CEO of Adragos Pharma to lead the company's next phase of operational execution and global site integration.

Adragos Pharma has appointed former FAMAR head Kostas Rengis as CEO to succeed founder Dr. Andreas Raabe.

Adragos Pharma has appointed Konstantinos Rengis as CEO to succeed founder Dr. Andreas Raabe.

Adragos Pharma acquired Sanofi's Maisons-Alfort facility, a major sterile injectables site, to enhance its European manufacturing network.

Adragos Pharma is acquiring Sanofi’s Kawagoe manufacturing site to become a top three CDMO in Japan and a strategic partner for Sanofi's local supply.

Adragos Pharma provides specialized aseptic fill and finish CDMO services, emphasizing early collaboration, quality, flexibility, and sustainability to support pharmaceutical development and manufacturing.

Comprehensive drug manufacturing services for various molecules with a focus on early-stage partnership and high-risk aseptic fill and finish operations.

Adragos Pharma is expanding its Japanese manufacturing facility to boost production capacity and quality, aiming to strengthen its pharmaceutical supply chain and client relationships.

Adragos Pharma's CCO discusses European onshoring in pharmaceutical outsourcing, emphasizing customer-focused service and end-to-end solutions for both large and small biopharma companies.

Adragos Pharma significantly expanded its Leipzig facility's liquid filling capacity with a new CGMP-compliant line, boosting production nearly tenfold to meet rising demand.

Adragos Pharma expanded its Leipzig facility with a new liquid filling line boosting production capacity nearly tenfold for pharmaceuticals and healthcare products.

Adragos Pharma expanded its sterile drug manufacturing by acquiring Baccinex and boosting ampoule production capacity with a new filling line.

Adragos Pharma acquired Swiss sterile fill/finish company Baccinex to boost its sterile manufacturing capabilities and global presence.

Adragos Pharma acquired Swiss sterile fill-finish firm Baccinex to expand its sterile manufacturing capabilities and global reach.